A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening

References

• Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014;e353–e365. doi:10.14694/EdBook_AM.2014.34.e35324857124
   PubMedGoogle Scholar
• Gonzalez DCD, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93(3):252–259. doi:10.1038/clpt.2012.23723361103
   PubMed Web of Science ®Google Scholar
• Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62(Suppl 1):S11–S14. doi:10.1016/j.metabol.2012.08.01622999010
   PubMed Web of Science ®Google Scholar
• Normanno N, Rachiglio AM, Roma C, et al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem. 2013;114(3):514–524. doi:10.1002/jcb.2440122991232
   PubMed Web of Science ®Google Scholar
• Kim H, Ruby AE, Shandilya HG, et al. T-blocker: a simple and robust probe-free quantitative PCR assay to detect somatic mutations down to 0.1% frequency. Biotechniques. 2018;65(4):205–210. doi:10.2144/btn-2018-011130284934
   PubMed Web of Science ®Google Scholar
• Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503–2516. doi:10.1093/nar/17.7.25032785681
   PubMed Web of Science ®Google Scholar
• Bolton L, Reiman A, Lucas K, Timms J, Cree IA. KRAS mutation analysis by PCR: a comparison of two methods. PLoS One. 2015;10(1):e115672. doi:10.1371/journal.pone.0115672
   Web of Science ®Google Scholar
• Morlan J, Baker J, Sinicropi D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One. 2009;4(2):e4584. doi:10.1371/journal.pone.000458419240792
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang J, Mostert B, et al. Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer. J Mol Diagn. 2013;15(1):62–69. doi:10.1016/j.jmoldx.2012.08.00723159590
   PubMed Web of Science ®Google Scholar
• Pender A, Garcia-Murillas I, Rana S, et al. Efficient genotyping of KRAS mutant non-small cell lung cancer using a multiplexed droplet digital PCR approach. PLoS One. 2015;10(9):e139074. doi:10.1371/journal.pone.0139074
   Web of Science ®Google Scholar
• Wood-Bouwens C, Lau BT, Handy CM, Lee H, Ji HP. Single-color digital PCR provides high-performance detection of cancer mutations from circulating DNA. J Mol Diagn. 2017;19(5):697–710. doi:10.1016/j.jmoldx.2017.05.00328818432
   PubMed Web of Science ®Google Scholar
• Qiu P, Shandilya H, D’Alessio JM, O’Connor K, Durocher J, Gerard GF. Mutation detection using Surveyor nuclease. Biotechniques. 2004;36(4):702–707. doi:10.2144/04364PF0115088388
   PubMed Web of Science ®Google Scholar
• Huang MC, Cheong WC, Lim LS, Li MH. A simple, high sensitivity mutation screening using Ampligase mediated T7 endonuclease I and Surveyor nuclease with microfluidic capillary electrophoresis. Electrophoresis. 2012;33(5):788–796. doi:10.1002/elps.20110046022437793
   PubMed Web of Science ®Google Scholar
• Tsuji T, Niida Y. Development of a simple and highly sensitive mutation screening system by enzyme mismatch cleavage with optimized conditions for standard laboratories. Electrophoresis. 2008;29(7):1473–1483. doi:10.1002/elps.20070072918300207
   PubMed Web of Science ®Google Scholar
• Wada T, Fukushima Y, Saitoh S. A new detection method for ATRX gene mutations using a mismatch-specific endonuclease. Am J Med Genet a. 2006;140(14):1519–1523. doi:10.1002/ajmg.a.3131016763962
   PubMed Web of Science ®Google Scholar
• Pagniez-Mammeri H, Lombes A, Brivet M, et al. Rapid screening for nuclear genes mutations in isolated respiratory chain complex I defects. Mol Genet Metab. 2009;96(4):196–200. doi:10.1016/j.ymgme.2008.12.00319167255
   PubMed Web of Science ®Google Scholar
• Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006;24(27):4517–4520. doi:10.1200/JCO.2006.06.612616983123
   PubMed Web of Science ®Google Scholar
• Qiu P, Shandilya H, Gerard GF. A method for clone sequence confirmation using a mismatch-specific DNA endonuclease. Mol Biotechnol. 2005;29(1):11–18. doi:10.1385/MB:29:1:1115668515
   PubMed Web of Science ®Google Scholar
• Oleykowski CA, Bronson MC, Godwin AK, Yeung AT. Mutation detection using a novel plant endonuclease. Nucleic Acids Res. 1998;26(20):4597–4602. doi:10.1093/nar/26.20.45979753726
   PubMed Web of Science ®Google Scholar
• Aggeli D, Karas VO, Sinnott-Armstrong NA, et al. Diff-seq: a high throughput sequencing-based mismatch detection assay for DNA variant enrichment and discovery. Nucleic Acids Res. 2018;46(7):e42. doi:10.1093/nar/gky02229361139
   PubMed Web of Science ®Google Scholar
• Wan JCM, Heider K, Gale D, et al. CtDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 2020;12(548):z8084. doi:10.1126/scitranslmed.aaz8084
   Web of Science ®Google Scholar
• Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12(524):x7533. doi:10.1126/scitranslmed.aax7533
   Web of Science ®Google Scholar
• Kandoth C, Mclellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339. doi:10.1038/nature1263424132290
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25(5):587–595. doi:10.1200/JCO.2006.07.358517290067
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi:10.1126/science.109931415118125
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi:10.1056/NEJMoa04093815118073
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–13311. doi:10.1073/pnas.040522010115329413
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346. doi:10.1093/jnci/dji05515741570
   PubMed Web of Science ®Google Scholar
• Keraite I, Alvarez-Garcia V, Garcia-Murillas I, et al. PIK3CA mutation enrichment and quantitation from blood and tissue. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-74086-w
   PubMed Web of Science ®Google Scholar
• Jin S, Zhu D, Shao F, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA. 2021;118(5):e2017421118. doi:10.1073/pnas.201742111833495330
   PubMed Web of Science ®Google Scholar
• Alvarez-Garcia V, Bartos C, Keraite I, et al. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Sci Rep. 2018;8(1):4290. doi:10.1038/s41598-018-22473-929523855
   PubMed Web of Science ®Google Scholar